Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

PAVmed stock price, quote, forecast and news

PAVM
US70387R1068
A2AQDJ

Price

1.09
Today +/-
-0.06
Today %
-6.22 %
P

PAVmed stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the PAVmed stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PAVmed stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PAVmed stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PAVmed's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PAVmed Stock Price History

DatePAVmed Price
9/6/20241.09 undefined
9/5/20241.16 undefined
9/4/20241.10 undefined
9/3/20241.19 undefined
8/30/20240.91 undefined
8/29/20240.84 undefined
8/28/20240.88 undefined
8/27/20240.91 undefined
8/26/20240.81 undefined
8/23/20240.74 undefined
8/22/20240.68 undefined
8/21/20240.73 undefined
8/20/20240.70 undefined
8/19/20240.69 undefined
8/16/20240.68 undefined
8/15/20240.70 undefined
8/14/20240.72 undefined
8/13/20240.74 undefined
8/12/20240.80 undefined

PAVmed Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into PAVmed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PAVmed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PAVmed’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PAVmed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PAVmed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PAVmed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PAVmed’s growth potential.

PAVmed Revenue, EBIT and net profit per share

DatePAVmed RevenuePAVmed EBITPAVmed Net Income
2029e311.51 M undefined0 undefined0 undefined
2028e243.37 M undefined47.23 M undefined0 undefined
2027e187.27 M undefined21.32 M undefined0 undefined
2026e102.61 M undefined-6.32 M undefined-4.14 M undefined
2025e19.05 M undefined-53.38 M undefined-27.24 M undefined
2024e4.83 M undefined-57.61 M undefined-62.81 M undefined
20232.45 M undefined-68.8 M undefined-66.27 M undefined
2022380,000 undefined-90.93 M undefined-89.26 M undefined
2021500,000 undefined-54.39 M undefined-50.63 M undefined
20200 undefined-23.35 M undefined-34.56 M undefined
20190 undefined-14.3 M undefined-16.73 M undefined
20180 undefined-10.56 M undefined-18.75 M undefined
20170 undefined-8.04 M undefined-10.4 M undefined
20160 undefined-5.65 M undefined-5.65 M undefined
20150 undefined-1.78 M undefined-1.78 M undefined
20140 undefined-270,000 undefined-270,000 undefined

PAVmed Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000002419102187243311
----------100.00375.00436.8483.3329.9527.98
----------150.00------
00000000-3-3000000
0-1-5-8-10-14-23-54-90-68-57-53-621470
----------3,400.00-1,425.00-278.95-5.8811.2319.34-
0-1-5-10-18-16-34-50-89-66-62-27-4000
--400.00100.0080.00-11.11112.5047.0678.00-25.84-6.06-56.45-85.19---
8.6211.2812.9713.522.2830.247.4377.5289.087.23000000
----------------
Details

Keystats

Revenue and Growth

The PAVmed Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PAVmed is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
0.840.770.631.548.246.2517.5277.9742.7522.31
00000002002061
0000000000
000000000278
00.010.110.090.220.291.424.461.161.85
0.840.780.741.638.466.5418.9482.6343.9324.5
000.020.020.04001.595.496.05
0000000000
0000000000
00000002.033.451.42
0000000000
00.440.11000.690.840.731.121.15
00.440.130.020.040.690.844.3510.068.62
0.841.220.871.658.57.2319.7886.9853.9933.12
                   
0.010.010.011.042.062.342.62.512.83
1.062.677.3714.0132.6247.5587.57198.07216.11237.6
-0.27-2.05-7.7-17.91-36.99-53.71-88.28-138.91-228.17-294.43
0000000000
0000000000
0.80.63-0.32-2.86-2.31-3.821.8961.67-9.26-53.83
0.010.170.950.861.742.352.973.32.71.79
0.030.410.240.711.331.392.334.263.717.41
00097000000777
00007.98.1414.96034.7944.2
0000000000
0.040.581.192.5410.9711.8820.267.5641.254.18
0001.94000000
0000000000
000000001.852.96
0001.9400001.852.96
0.040.581.194.4810.9711.8820.267.5643.0557.14
0.841.210.871.628.668.0622.1569.2333.793.31
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of PAVmed provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PAVmed's financial health and stability.

Assets

PAVmed's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PAVmed must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PAVmed after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PAVmed's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
0-1-5-9-18-17-35-56-103-79
0000000022
0000000000
00001,00000-1,00001,000
00028313163022
0000000000
0000000000
0-1-4-6-8-13-21-40-70-52
0000000-1-10
0000000-3-40
0000000-2,000-3,0001,000
0000000000
00042516-14359
010313516120121
01471511331043831
0040000-110
0000000000
00006-21160-37-20
-0.03-1.25-4.47-6.62-8.82-13.39-21.97-42.06-72.53-52.28
0000000000

PAVmed stock margins

The PAVmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PAVmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PAVmed.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PAVmed's sales revenue. A higher gross margin percentage indicates that the PAVmed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PAVmed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PAVmed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PAVmed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PAVmed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PAVmed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PAVmed Margin History

PAVmed Gross marginPAVmed Profit marginPAVmed EBIT marginPAVmed Profit margin
2029e-161.83 %0 %0 %
2028e-161.83 %19.41 %0 %
2027e-161.83 %11.38 %0 %
2026e-161.83 %-6.16 %-4.04 %
2025e-161.83 %-280.23 %-142.98 %
2024e-161.83 %-1,192.29 %-1,299.81 %
2023-161.83 %-2,805.67 %-2,702.69 %
2022-852.63 %-23,928.95 %-23,489.47 %
2021-18 %-10,878 %-10,126 %
2020-161.83 %0 %0 %
2019-161.83 %0 %0 %
2018-161.83 %0 %0 %
2017-161.83 %0 %0 %
2016-161.83 %0 %0 %
2015-161.83 %0 %0 %
2014-161.83 %0 %0 %

PAVmed Stock Sales Revenue, EBIT, Earnings per Share

The PAVmed earnings per share therefore indicates how much revenue PAVmed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue PAVmed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PAVmed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PAVmed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PAVmed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PAVmed Revenue, EBIT and net profit per share

DatePAVmed Sales per SharePAVmed EBIT per sharePAVmed Earnings per Share
2029e29.92 undefined0 undefined0 undefined
2028e23.38 undefined0 undefined0 undefined
2027e17.99 undefined0 undefined0 undefined
2026e9.86 undefined0 undefined-0.4 undefined
2025e1.83 undefined0 undefined-2.62 undefined
2024e0.46 undefined0 undefined-6.03 undefined
20230.34 undefined-9.51 undefined-9.16 undefined
20220 undefined-1.02 undefined-1 undefined
20210.01 undefined-0.7 undefined-0.65 undefined
20200 undefined-0.49 undefined-0.73 undefined
20190 undefined-0.47 undefined-0.55 undefined
20180 undefined-0.47 undefined-0.84 undefined
20170 undefined-0.6 undefined-0.77 undefined
20160 undefined-0.44 undefined-0.44 undefined
20150 undefined-0.16 undefined-0.16 undefined
20140 undefined-0.03 undefined-0.03 undefined

PAVmed business model

PAVmed Inc is a US company that was founded in 2014 with the goal of developing and bringing innovative medical products to market. The company is headquartered in New York City and is listed on the NASDAQ stock exchange. The history of PAVmed Inc began with a focus on developing medical implants and devices. Founder and CEO Lishan Aklog had a desire to develop high-quality medical products that meet the needs of patients and doctors alike. Through his experience as a medical director at Beth Israel Hospital in Boston, he was able to draw on an extensive network of doctors, scientists, and experts. Over the years, PAVmed Inc's business model has expanded. Today, the company not only focuses on the development of medical devices but also on the sale of products from other manufacturers as well as research and development in the field of medical technology. Overall, PAVmed Inc's business is divided into three main divisions: medical products, commercial products, and biopharmaceuticals. These areas are described in more detail below: Medical products: PAVmed Inc develops and markets a wide range of medical products and implants, including devices for minimally invasive surgery. These include products for the treatment of vascular diseases, varicose veins, urinary stress incontinence, as well as for endoscopic diagnosis and therapy. Commercial products: PAVmed Inc also distributes products from other manufacturers, such as medical instruments, implants, and consumable materials. These are products that are used daily in clinical practice and are an important part of routine patient care. Biopharmaceuticals: PAVmed Inc is also involved in biopharmaceutical research and is currently developing a new generation of drugs for the treatment of diseases such as cancer, rheumatism, and inflammatory bowel disease. The company relies on innovative drug delivery systems that allow drugs to be delivered effectively and safely in the body. In recent years, PAVmed Inc has introduced some notable products to the market. This includes the CarpX™ system, which is used for minimally invasive treatment of varicose veins. The system allows for the removal of varicose veins without incisions or scars by introducing a special thread into the affected vessel and clotting it there. Another product is the DisappEAR™ Ear Tube, which is used to treat middle ear infections in children. Unlike conventional ear plugs that need to be regularly replaced, the DisappEAR Ear Tube is designed to dissolve on its own after a certain period of time, eliminating the need for irritation. PAVmed Inc aims to usher in a new era of medical technology that takes into account the needs of patients and doctors equally. To achieve this, the company relies on innovative technologies and close collaboration with clinicians and scientists around the world. Through research and development, PAVmed Inc plans to continue bringing groundbreaking products to the market that contribute to improving the lives of patients. PAVmed is one of the most popular companies on Eulerpool.com.

PAVmed SWOT Analysis

Strengths

PAVmed Inc possesses a robust intellectual property portfolio, consisting of innovative medical device products and technologies. This strong IP position provides legal protection and competitive advantage.

The company benefits from a skilled and seasoned management team with extensive expertise in the healthcare industry. Their knowledge and leadership contribute to effective decision-making and strategic planning.

Weaknesses

One challenge faced by PAVmed Inc is the limited financial resources available. This constraint may hinder the company's ability to fully execute its growth strategies and R&D activities.

PAVmed Inc relies on certain key suppliers for the procurement of components and materials necessary for its products. Any disruption in the supply chain could adversely impact the company's operations.

Opportunities

The constantly growing market for medical devices presents a significant opportunity for PAVmed Inc. The increasing demand for innovative and cost-effective healthcare solutions offers the company a chance to capture a larger market share.

The rapid pace of technological advancements in the medical device industry opens up new avenues for PAVmed Inc to develop and commercialize cutting-edge products. Embracing new technologies can further enhance the company's competitive position.

Threats

PAVmed Inc operates in a highly competitive market, facing competition from established players as well as emerging startups. The presence of numerous competitors poses the risk of pricing pressures, loss of market share, and limited customer reach.

As a medical device company, PAVmed Inc is subject to strict regulations and approvals from regulatory bodies. Non-compliance or delays in obtaining necessary approvals can impede product development and commercialization, resulting in potential revenue loss.

PAVmed Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PAVmed historical P/E ratio, EBIT, and P/S ratio.

PAVmed shares outstanding

The number of shares was PAVmed in 2023 — This indicates how many shares 7.232 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue PAVmed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PAVmed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PAVmed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PAVmed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PAVmed Stock splits

In PAVmed's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for PAVmed.

PAVmed latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.48 -1.19  (19.72 %)2024 Q2
3/31/2024-1.71 -2.62  (-53.5 %)2024 Q1
12/31/2023-1.93 -1.81  (6.11 %)2023 Q4
9/30/2023-2.09 -2.4  (-14.77 %)2023 Q3
6/30/2023-2.91 -2.1  (27.76 %)2023 Q2
3/31/2023-3.16 -2.85  (9.87 %)2023 Q1
12/31/2022-3.88 -3.45  (10.99 %)2022 Q4
9/30/2022-0.27 -0.29  (-7.29 %)2022 Q3
6/30/2022-0.23 -0.29  (-23.61 %)2022 Q2
3/31/2022-0.2 -0.2  (-0.55 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the PAVmed stock

Eulerpool World ESG Rating (EESG©)

31/ 100

🌱 Environment

33

👫 Social

38

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PAVmed list of shareholders

%
Name
Stocks
Change
Date
3.68 % Ayrton Capital LLC382,976233,36012/31/2023
2.91 % The Vanguard Group, Inc.302,60648,83412/31/2023
2.85 % Pavilion Venture Partners, L.L.C.297,10504/25/2023
1.92 % First Manhattan Co. LLC200,000133,33312/31/2023
0.78 % Glennon (Michael J)81,66765,0002/22/2024
0.77 % Aklog (Lishan)80,05704/25/2023
0.72 % BlackRock Institutional Trust Company, N.A.74,922412/31/2023
0.62 % White (Debra Jayne)65,00065,0002/22/2024
0.62 % Cox (James L)65,00065,0002/22/2024
0.62 % Sparks (Ronald M)65,00065,0002/22/2024
1
2
3
4
5
...
10

PAVmed Executives and Management Board

Dr. Lishan Aklog57
PAVmed Chairman of the Board, Chief Executive Officer
Compensation 1.45 M
Mr. Shaun O'Neil41
PAVmed Chief Operating Officer, Executive Vice President
Compensation 1.44 M
Mr. Dennis Mcgrath66
PAVmed President, Chief Financial Officer
Compensation 1.11 M
Dr. Brian Deguzman59
PAVmed Chief Technology Officer, Chief Compliance Officer (since 2014)
Compensation 593,100
Ms. Joan Harvey56
PAVmed Independent Director
Compensation 338,736
1
2
3

Most common questions regarding PAVmed

What values and corporate philosophy does PAVmed represent?

PAVmed Inc represents a set of core values and corporate philosophy that drive its operations. The company prioritizes innovation, seeking to develop and commercialize cutting-edge medical devices and technologies. PAVmed Inc is dedicated to enhancing patient outcomes and providing effective healthcare solutions. The company also focuses on efficiency and cost-effectiveness, aiming to deliver products and services that maximize value for patients, healthcare providers, and other stakeholders. PAVmed Inc values collaboration and partnerships, working with industry experts, physicians, and other key stakeholders to foster advancements in medical technology. Overall, the company strives to uphold its commitment to innovation, efficiency, and collaboration in the healthcare industry.

In which countries and regions is PAVmed primarily present?

PAVmed Inc is primarily present in the United States.

What significant milestones has the company PAVmed achieved?

PAVmed Inc has achieved several significant milestones. Some notable accomplishments include the successful launch and commercialization of its innovative medical devices. The company introduced CarpX, a minimally invasive device for carpal tunnel syndrome, which received 510(k) clearance from the FDA. PAVmed also achieved the FDA clearance for its EsoGuard esophageal DNA test, revolutionizing the detection of esophageal cancer. Additionally, the company expanded its product portfolio with the acquisition of Solys Medical, broadening its presence in the urology market. PAVmed Inc continues to make strides in advancing healthcare through groundbreaking technologies and strategic partnerships.

What is the history and background of the company PAVmed?

PAVmed Inc is a medical device company that focuses on the development and commercialization of innovative products in the healthcare sector. Founded in 2014, PAVmed Inc has aimed to address unmet medical needs through its proprietary technologies and collaborations with renowned medical institutions. With a diverse portfolio encompassing devices and procedures across different specialties, the company is committed to improving patient outcomes and enhancing healthcare delivery. PAVmed Inc has steadily grown its presence in the medical industry and continues to strive towards developing groundbreaking solutions to improve the quality of patient care.

Who are the main competitors of PAVmed in the market?

The main competitors of PAVmed Inc in the market include companies like Johnson & Johnson, Medtronic, Boston Scientific Corporation, and Integra Lifesciences Holdings Corporation.

In which industries is PAVmed primarily active?

PAVmed Inc is primarily active in the medical technology industry.

What is the business model of PAVmed?

PAVmed Inc is a medical technology company focused on developing and commercializing innovative products for the healthcare industry. The company's business model revolves around identifying unmet medical needs and creating innovative solutions to address them. PAVmed focuses on the development and commercialization of medical devices and technologies that have the potential to significantly improve patient outcomes and revolutionize the healthcare sector. Through strategic partnerships, acquisitions, and internal research and development, PAVmed Inc aims to bring cutting-edge products to market and provide value to patients, physicians, and healthcare providers.

What is the P/E ratio of PAVmed 2024?

The PAVmed P/E ratio is -0.13.

What is the P/S ratio of PAVmed 2024?

The PAVmed P/S ratio is 1.63.

What is the AlleAktien quality score of PAVmed?

The AlleAktien quality score for PAVmed is 5/10.

What is the revenue of PAVmed 2024?

The expected PAVmed revenue is 4.83 M USD.

How high is the profit of PAVmed 2024?

The expected PAVmed profit is -62.81 M USD.

What is the business model of PAVmed

PAVmed Inc. is an American company specializing in the development of medical devices and products. Their business model includes various divisions targeting the needs of different markets. The company focuses on developing innovative medical technology solutions that solve problems for patients and doctors. One of PAVmed's key divisions is the development of medical devices, such as the CarpX™ technology for minimally invasive hand surgery or the PortIO™ system designed for quick, secure, and hygienic access to the bloodstream in chemotherapy patients. PAVmed works closely with certified surgeons and physicians to develop devices that meet the highest standards to ensure optimal patient care. Another important division of PAVmed is the development of healthcare products. These include the NextCath system, which enables safe and easy catheterization, and the DisappEAR ear spray, which treats and prevents acute ear infections. PAVmed's healthcare products aim to improve patients' quality of life while also facilitating the work of medical professionals. PAVmed also operates an IT division specializing in the development of software solutions for the medical industry. These include the analysis of diagnostic data, organization of patient data, and the development of virtual treatment options. PAVmed has also developed an electronic patient record to provide patients with a clearer overview of their medical history and improve information exchange between doctors and patients. PAVmed relies on partnerships and collaborations to strengthen its business model and drive the development of innovative solutions. The company works closely with other medical technology companies, universities, and research institutions to create synergies and accelerate the development of new technologies and products. PAVmed's business model is based on researching and developing high-quality and innovative solutions for the healthcare industry. Through close collaboration with experienced professionals and the use of the latest technologies, PAVmed has been able to develop a wide portfolio of products and services tailored to the specific needs of different markets. The company relies on partnerships and collaborations to achieve synergistic effects and focuses on meeting the highest quality standards. In this way, PAVmed offers a wide range of solutions for the needs of patients and medical professionals.

What is the PAVmed dividend?

PAVmed pays a dividend of 0 USD distributed over payouts per year.

How often does PAVmed pay dividends?

The dividend cannot currently be calculated for PAVmed or the company does not pay out a dividend.

What is the PAVmed ISIN?

The ISIN of PAVmed is US70387R1068.

What is the PAVmed WKN?

The WKN of PAVmed is A2AQDJ.

What is the PAVmed ticker?

The ticker of PAVmed is PAVM.

How much dividend does PAVmed pay?

Over the past 12 months, PAVmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PAVmed is expected to pay a dividend of 0 USD.

What is the dividend yield of PAVmed?

The current dividend yield of PAVmed is .

When does PAVmed pay dividends?

PAVmed pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PAVmed?

PAVmed paid dividends every year for the past 0 years.

What is the dividend of PAVmed?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PAVmed located?

PAVmed is assigned to the 'Health' sector.

Wann musste ich die Aktien von PAVmed kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PAVmed from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did PAVmed pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of PAVmed in the year 2023?

In the year 2023, PAVmed distributed 0 USD as dividends.

In which currency does PAVmed pay out the dividend?

The dividends of PAVmed are distributed in USD.

All fundamentals about PAVmed

Our stock analysis for PAVmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PAVmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.